Beijing Airdoc Technology Co., Ltd. logo

Beijing Airdoc Technology Co., Ltd.

2251.HK

HKSEHealthcareMedical - Diagnostics & Research

Latest quote

HK$9.57

−HK$0.83 · -7.98%

Aug 24, 11:02 AM HKT

2251.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
CN
CEO
Da Lei Zhang
Listed since
Nov 5, 2021
Employees
181

Market position

52-week range

Current HK$9.57

Open
HK$9.57
Previous close
HK$10.40
Volume
100
0× average
Average volume
45.2K
Average daily volume
Market cap
966.87M HKD
Beta
0.8
Market reference 1
50-day average
HK$10.3792
-7.80% below average
200-day average
HK$11.3465
-15.66% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-34.7×
P/B (TTM)
0.69×
P/S (TTM)
4.78×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
73.53%
Operating margin
-20.99%
Net margin
-14.41%

Financial health

Debt / equity
0.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends102%-12%-127%-241%Gross margin, FY2021: 60.98%Gross margin, FY2022: 49.14%Gross margin, FY2023: 61.35%Gross margin, FY2024: 55.43%Gross margin, FY2025: 73.49%Operating margin, FY2021: -123.48%Operating margin, FY2022: -212.38%Operating margin, FY2023: -91.26%Operating margin, FY2024: -129.07%Operating margin, FY2025: -20.99%Net margin, FY2021: -123.83%Net margin, FY2022: -158.37%Net margin, FY2023: -64.98%Net margin, FY2024: -163.37%Net margin, FY2025: -14.41%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 60.98%. Gross margin FY2022 49.14%. Gross margin FY2023 61.35%. Gross margin FY2024 55.43%. Gross margin FY2025 73.49%. Operating margin FY2021 -123.48%. Operating margin FY2022 -212.38%. Operating margin FY2023 -91.26%. Operating margin FY2024 -129.07%. Operating margin FY2025 -20.99%. Net margin FY2021 -123.83%. Net margin FY2022 -158.37%. Net margin FY2023 -64.98%. Net margin FY2024 -163.37%. Net margin FY2025 -14.41%.

Income trends

Revenue

173.26M HKD+10.80%

Operating income

−36.37M HKD+81.98%

Net income

−24.98M HKD+90.22%
Income trends across reported periods249.91M HKD66.14M HKD−117.63M HKD−301.4M HKDRevenue, FY2021: 115.18M HKDRevenue, FY2022: 113.66M HKDRevenue, FY2023: 203.96M HKDRevenue, FY2024: 156.37M HKDRevenue, FY2025: 173.26M HKDOperating income, FY2021: −142.23M HKDOperating income, FY2022: −241.38M HKDOperating income, FY2023: −186.14M HKDOperating income, FY2024: −201.83M HKDOperating income, FY2025: −36.37M HKDNet income, FY2021: −142.63M HKDNet income, FY2022: −180M HKDNet income, FY2023: −132.53M HKDNet income, FY2024: −255.46M HKDNet income, FY2025: −24.98M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 115.18M HKD. Revenue FY2022 113.66M HKD. Revenue FY2023 203.96M HKD. Revenue FY2024 156.37M HKD. Revenue FY2025 173.26M HKD. Operating income FY2021 −142.23M HKD. Operating income FY2022 −241.38M HKD. Operating income FY2023 −186.14M HKD. Operating income FY2024 −201.83M HKD. Operating income FY2025 −36.37M HKD. Net income FY2021 −142.63M HKD. Net income FY2022 −180M HKD. Net income FY2023 −132.53M HKD. Net income FY2024 −255.46M HKD. Net income FY2025 −24.98M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue173.26M HKD156.37M HKD203.96M HKD113.66M HKD115.18M HKD
Cost of goods sold45.94M HKD69.69M HKD78.83M HKD57.81M HKD44.94M HKD
Gross profit127.33M HKD86.68M HKD125.13M HKD55.85M HKD70.24M HKD
Research and development58.1M HKD101.69M HKD111.64M HKD125.59M HKD64.27M HKD
Selling, general, and administrative105.6M HKD186.81M HKD199.63M HKD180.08M HKD149.65M HKD
Operating expenses163.7M HKD327.7M HKD311.27M HKD298.63M HKD211.02M HKD
Interest income14.6M HKD15.24M HKD13.02M HKD9.14M HKD2.02M HKD
Interest expense336.07K HKD229K HKD545K HKD439K HKD298K HKD
Depreciation and amortization20.24M HKD23.48M HKD31.95M HKD22.67M HKD15.5M HKD
Operating income−36.37M HKD−201.83M HKD−186.14M HKD−241.38M HKD−142.23M HKD
Net income−24.98M HKD−255.46M HKD−132.53M HKD−180M HKD−142.63M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.24

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.02-0.67-1.32-1.97Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26
Q3 2022, reported Aug 25, 2022: actual -1.15, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 23, 2023: actual -0.866, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 25, 2023: actual -0.389, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual -1.01, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual -0.849, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual -1.83, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual -0.022, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual -0.245, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates389.24M278.49M167.74M57MQ1 '23MissQ3 '23MissQ1 '24MissQ3 '24No estimateQ1 '25MissQ3 '25No estimateQ1 '26No estimateQ3 '26Estimate
Q1 2023, reported Mar 23, 2023: actual 86.03M HKD, estimate 237.66M HKD, surprise -63.80%, Miss. Q3 2023, reported Aug 25, 2023: actual 89.16M HKD, estimate 365.37M HKD, surprise -75.60%, Miss. Q1 2024, reported Mar 27, 2024: actual 133.12M HKD, estimate 364.54M HKD, surprise -63.48%, Miss. Q3 2024, reported Aug 28, 2024: actual 100.69M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 67.05M HKD, estimate 91.59M HKD, surprise -26.79%, Miss. Q3 2025, reported Aug 28, 2025: actual 91.73M HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual 99.62M HKD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 28, 2026: actual —, estimate 111.59M HKD, surprise —, Comparison unavailable.

2251.HK peers

Continue in GoAI

Research 2251.HK

research.disclaimer